

## **PRESS RELEASE**

**Clifton Mining Company Inc. (OTC : CFTN)**  
**FOR RELEASE – February 12, 2007**

### **ABL END OF YEAR SUMMARY INFORMATION**

American Biotech Labs (ABL) is a private company in which Clifton Mining Company (Clifton) is the largest individual shareholder.

#### Annual Sales

American Biotech Labs annual sales continued to grow at more than 20%. All market sectors grew, with the fastest growth occurring in sales of products to doctors and new volume purchase contracts. Numerous new domestic and international contracts have been signed, many within the last two months. The largest single order in January 2007 was 130,000 bottles.

#### New Products

ABL is planning to release four (4) new products in 2007, three (3) of which are expected to be launched during the second quarter. Two new gel products are awaiting approval and will be released when approved. Both domestic and international clients are already testing these new products. Filings have been made internationally in the hope that new products can move quickly into these markets.

#### Military Special Operations

American Biotech Labs was invited to be and has become an active member of the United States Special Operations Medical Association. This association is dedicated to the health and welfare of US Special Operations Medics and the soldiers they care for. American Biotech Labs has been supplying product to many of these medics who work in Iraq and to US Air Marshals and fire fighters who are also part of the association.

#### Full Information Summary, Fact Sheet

Said Keith Moeller, a Managing Director, “2006 was an outstanding year for ABL but with the new accounts the company has recently signed, we expect 2007 to be substantially better. A great deal of time and money has been expended in building an impressive intellectual property foundation. ABL’s reputation as a world leader in silver technology continues to broaden, as documented by papers in prestigious professional peer-reviewed journals.”

Management has completed a year-end summary which will shortly be available on the American Biotech Labs listing on Clifton’s website home page at [www.cliftonmining.com](http://www.cliftonmining.com). If you click on the American Biotech Labs button, the new summary will appear third on the list.

## New Patent Information

The unique SilverSol Technology™ created and owned by ABL now has a patented construction process, patented particle sizes and many patented end uses. The patent covers a wide range of pathogens, including: Anthrax and the bacteria that cause Bubonic plague; and Viruses such as Hepatitis B and HIV; and, Parasitic diseases such as Malaria. The patent also includes more common infectious agents and ailments ranging from MRSA to TB, from UTIs to skin infections, ear and eye infections, upper respiratory tract infections, STD's, and others.

The company is now working with military, government, university, and medical organizations to study and develop additional uses for the products and the technology. Information on our most recent patent can be accessed through the patent link button on the ABL website. The website also has a direct link to the peer review antibiotic synergy study article.

Clifton trades on the U.S. OTC: (CFTN). For additional information, contact Dr. Ken Friedman, President at 303-642-0659, Keith Moeller Vice President at 801-756-1414 or see our websites at [www.cliftonmining.com](http://www.cliftonmining.com) or at [www.americanbiotechlabs.com](http://www.americanbiotechlabs.com).

###

Note: Any statements released by Clifton Mining Company that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward looking statements invoke risk and uncertainties that may affect the company's business prospects and performance.